Difference between revisions of "Levamisole (Ergamisol)"
Jump to navigation
Jump to search
m |
|||
| Line 4: | Line 4: | ||
*[[Breast cancer - historical|Breast cancer]] | *[[Breast cancer - historical|Breast cancer]] | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *6/18/1990: indicated as adjuvant treatment in combination with [[Fluorouracil (5-FU)|5-fluorouracil]] after surgical resection in patients with Dukes' stage C [[colon cancer]]. | + | *6/18/1990: indicated as adjuvant treatment in combination with [[Fluorouracil (5-FU)|5-fluorouracil]] after surgical resection in patients with Dukes' stage C [[colon cancer]]. ''(Based on Laurie et al. 1989 & Moertel et al. 1990)'' |
==Also known as== | ==Also known as== | ||
Revision as of 01:02, 4 September 2022
This agent is not commercially available in the United States and is included for historic purposes only.
Diseases for which it was used
History of changes in FDA indication
- 6/18/1990: indicated as adjuvant treatment in combination with 5-fluorouracil after surgical resection in patients with Dukes' stage C colon cancer. (Based on Laurie et al. 1989 & Moertel et al. 1990)
Also known as
- Brand name: Ergamisol